Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 1/20 | 0.55 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31235811 | 0.89 | CPB1 (0.59) | CPB1CPB2CAPN1SIRT2SIRT1 | |
| SCHEMBL29576990 | 0.89 | ECE1 (0.63) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL20677235 | 0.88 | CPB1 (0.56) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL10035700 | 0.86 | CTSK (0.55) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL10035721 | 0.86 | CTSK (0.55) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL29674796 | 0.86 | ECE1 (0.59) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL31094970 | 0.86 | SIRT1 (0.56) | CPB1CPB2SIRT2SIRT1SIRT3 | |
| SCHEMBL12022502 | 0.85 | CTSK (0.60) | CAPN1CTSLCTSKCTSBCTSS | |
| SCHEMBL19036901 | 0.85 | CTSK (0.60) | CAPN1CTSLCTSKCTSBCTSS | |
| SCHEMBL27899929 | 0.85 | CTSK (0.60) | CAPN1CTSLCTSKCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392560-B1 | CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNA | UNIV BEIJING (CN) | 2026-03-11 | — | — | EP | claimed |
| US-20250223321-A1 | RESPIRATORY SYNCYTIAL VIRUS RECOMBINANT FUSION PROTEIN WITH PRE-FUSION CONFORMATION, PREPARATION METHOD AND USES THEREOF | BEIJING BENEWILL TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-07-10 | — | — | US | claimed |
| EP-4578878-A1 | RESPIRATORY SYNCYTIAL VIRUS RECOMBINANT FUSION PROTEIN HAVING PRE-FUSION CONFORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Benewill Technology Development Co., Ltd. (CN) | 2025-07-02 | — | — | EP | claimed |
| EP-4467573-A1 | BISPECIFIC BINDING MOLECULE | Yichen Therapeutics Limited (HK) | 2024-11-27 | — | — | EP | claimed |
| WO-2024067723-A1 | RESPIRATORY SYNCYTIAL VIRUS RECOMBINANT FUSION PROTEIN HAVING PRE-FUSION CONFORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京百邑无忧科技发展有限公司 | 2024-04-04 | — | — | WO | claimed |
| EP-4240860-A1 | DETECTION OF ENVIRONMENTAL INFLUENCES BY BIOLUMINESCENCE | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen (DE) | 2023-09-13 | — | — | EP | claimed |
| EP-3480316-B1 | LENTIVIRAL VECTOR PARTICLES HAVING IMPROVED TRANSDUCTION EFFICIENCY FOR CELLS EXPRESSING DC-SIGN | IMMUNE DESIGN CORP (US) | 2022-09-14 | — | — | EP | claimed |
| WO-2022096479-A1 | DETECTION OF ENVIRONMENTAL INFLUENCES BY BIOLUMINESCENCE | RHEINISCH-WESTFÄLISCHE TECHNISCHE HOCHSCHULE (RWTH) AACHEN (DE) | 2022-05-12 | — | — | WO | claimed |
| CN-114437193-A | Gold-melittin nano hybrid and application thereof | 陕西未来多肽生物科技有限公司 | 2022-05-06 | — | — | CN | claimed |
| EP-3402811-B1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | NOVO NORDISK AS (DK) | 2022-03-30 | — | — | EP | claimed |
| US-20260137810-A1 | GENE THERAPY VECTORS FOR THE EXPRESSION OF PREPRODYNORPHIN VARIANTS FOR THE TREATMENT OF EPILEPSY | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2026-05-21 | — | — | US | disclosed |
| US-12600783-B2 | Anti-New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen-binding proteins and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260097105-A1 | SYSTEMS, FORMULATIONS AND METHODS FOR GENERATING UNIVERSAL PEPTIDE/MHC COMPLEXES WITH ENGINEERED DISULFIDE CONNECTING THE HEAVY AND LIGHT CHAINS | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12584107-B2 | T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells | 3T BIOSCIENCES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4705316-A2 | ANTIBODIES TARGETING HUMAN LEUKOCYTE ANTIGEN CATHEPSIN G PEPTIDE COMPLEX | Board of Regents, The University of Texas System (US) | 2026-03-11 | — | — | EP | disclosed |
| US-11286289-B2 | T cell receptors | ADAPTIMMUNE LIMITED (GB) | 2022-03-29 | — | — | US | disclosed |
| US-11285196-B2 | Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof | BASEUNY ESLAM ABBAS (EG) | 2022-03-29 | — | — | US | disclosed |
| EP-3740216-B1 | METHODS OF ASSESSING TRANSDUCTION POTENCY OF VIRAL VECTORS | IMMATICS US INC (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3578188-B1 | T CELL RECEPTORS | ADAPTIMMUNE LTD (GB) | 2022-02-23 | — | — | EP | disclosed |
| EP-3193917-B9 | VACCINE COMPOSITIONS COMPRISING TRYPTOPHAN 2,3-DIOXYGENASE OR FRAGMENTS THEREOF | IO BIOTECH APS (DK) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097105-A1 | SYSTEMS, FORMULATIONS AND METHODS FOR GENERATING UNIVERSAL PEPTIDE/MHC COMPLEXES WITH ENGINEERED DISULFIDE CONNECTING THE HEAVY AND LIGHT CHAINS | HLA-DRB1, MICA, FTH1 | CPB1 4298/4885CPB2 4398/4885CAPN1 4185/4885 |
| US-20260137810-A1 | GENE THERAPY VECTORS FOR THE EXPRESSION OF PREPRODYNORPHIN VARIANTS FOR THE TREATMENT OF EPILEPSY | PREP, NPY1R, PSD | CPB1 1272/4885CPB2 2316/4885CAPN1 673/4885 |
| US-12600783-B2 | Anti-New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen-binding proteins and methods of use thereof | TAP1, MICA, CD74 | CPB1 1207/4885CPB2 2802/4885CAPN1 2955/4885 |
| US-12584107-B2 | T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells | MICA, CD74, CD14 | CPB1 1866/4885CPB2 2171/4885CAPN1 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.